ABO 202 - Arbor Biotechnologies
Alternative Names: ABO-202 - Arbor BiotechnologiesLatest Information Update: 03 Aug 2023
At a glance
- Originator Arbor Biotechnologies
- Class Gene therapies
- Mechanism of Action Gene expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 24 Jul 2023 ABO 202 - Arbor Biotechnologies is available for licensing as of 24 Jul 2023. https://arbor.bio/who-we-are/
- 18 Jul 2023 Early research in CNS disorders in USA (Parenteral) (Arbor Biotechnologies pipeline, July 2023)